Enzon Pharmaceuticals, Inc.
ENZN
$0.04
-$0.01-13.33%
OTC PK
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -27.07% | -68.66% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -27.07% | -68.66% | |||
| Operating Income | 27.07% | 68.66% | |||
| Income Before Tax | 21.71% | -104.36% | |||
| Income Tax Expenses | 138.10% | -321.05% | |||
| Earnings from Continuing Operations | 16.77% | -88.93% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 16.77% | -88.93% | |||
| EBIT | 27.07% | 68.66% | |||
| EBITDA | -- | -- | |||
| EPS Basic | 10.73% | -44.37% | |||
| Normalized Basic EPS | 37.50% | 137.21% | |||
| EPS Diluted | 2.44% | -44.37% | |||
| Normalized Diluted EPS | 37.50% | 137.21% | |||
| Average Basic Shares Outstanding | 0.00% | 0.00% | |||
| Average Diluted Shares Outstanding | 0.00% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | 1.00% | |||